ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Entera Bio Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.94+0.26 (+9.70%)
Close on Oct 19, 2026
- Market cap
- $148.33M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
0.0%−17.8 pts over 5 years
Operating margin
-27450.0%−24390.3 pts over 5 years
Net margin
-27235.7%−24162.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -76.8% | -32.1% | -35.1% | – | |
| EPS, diluted | 0.0% | -17.8% | -17.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -105.4% | -108.0% | |
| Return on assets | – | -84.9% | -90.1% | |
| Current ratio | – | 4.95 | 6.94 | |
| Capex to revenue | – | 14.5% | 254.8% | |
| Diluted shares | 7M | 18M | 46M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Entera Bio generated $43.06M from operations and spent $191.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$43.06M
Used
$191.00K
Capital expenditure$191.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-27235.7%
×Asset turnover0.00×
×Equity multiplier1.20×
=Return on equity, FY2025-108.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -27235.7% | 0.00× | 1.20× | -108.0% |
| FY2024 | -5271.3% | 0.02× | 1.15× | -103.3% |
| FY2022 | -9754.5% | 0.01× | 1.14× | -76.2% |
| FY2021 | -2134.3% | 0.03× | 1.19× | -81.0% |
| FY2020 | -3072.9% | 0.03× | 1.24× | -105.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$11.44M
- Cash generatingOperating cash flow above zero-$7.37M
- Return on assets improvedROA up on the prior year-81.1% → -121.8%
- Earnings backed by cashOperating cash flow above net income-$7.37M vs -$11.44M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.63 → 6.94
- No dilutionShare count did not rise38M → 46M
- Gross margin improvedGross margin up on the prior year4.97% → 0.00%
- More efficientAsset turnover rose0.02 → 0.00